Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

@article{Arnold2005OctreotideVO,
  title={Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.},
  author={Rudolf Arnold and Anja Rinke and K. Klose and H. -A. M{\"u}ller and Matthias U Wied and Karin Zamzow and Christina Schmidt and Carmen Schade-Brittinger and Peter Josef Barth and Roland Moll and Michael Koller and Michael Unterhalt and Wolfgang Hiddemann and Martin Schmidt-Lauber and Marianne Ellen Pavel and Christian N. Arnold},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2005},
  volume={3 8},
  pages={761-71}
}
BACKGROUND & AIMS The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancreatic) and midgut tumors. METHODS One hundred nine of 125 registered patients were randomized starting in January 1995, and 105 patients (51 monotherapy, 54 combination treatment… CONTINUE READING